Client Result
Carlyle and SK Capital Complete Acquisition of bluebird bio
2 minute read | June.12.2025

2 minute read | June.12.2025
2 minute read | October.10.2024
Ipsen has agreed to sell its rare pediatric disease priority review voucher to a large global pharmaceutical company for $158 million.
2 minute read | January.17.2024
1 minute read | January.09.2023
August.31.2022
Advised NextCapital, an open-architecture digital retirement advice provider based in Chicago, on its acquisition by Goldman Sachs.
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
May.03.2022
March.30.2022